BIOXCEL THERAPEUT DL-,001 WKN: A2JF20 ISIN: US09075P1057 Kürzel: BTAI Forum: Aktien Thema: Hauptdiskussion

Ich befürchte das schlimmste und hoffe für Alle die hier investiert sind das Beste.

Klingt wie, Taschen füllen bevor es kracht. Bin echt gespannt was hier die tage passiert

🤣👍

Weil er davon ausgeht, dass der Kurs bald tiefer steht.

Vielen herzlichen Dank für diese raschen Informationen und konstruktiven Beiträge im Sinne der allgemeinen Zufriedenheit und Volksaufklärungsstrategien. Jetzt sollte es locker weiter gehen in Richtung Nord-Nord-Ost-Flanke! Bitte nicht beleidigen. Danke und Kondenswasser beachten - FOMO-Effekt greift voll zu! :-)

Danke mein bester!

Es ist jetzt aber in so kurzer Zeit echt gut gefallen. Es gibt ja auch nichts was den Kurs halten würde... eher im Gegenteil

1.30 ist ok :-) solange es nicht tiefergeht

Moin. Puh 1,30. Das ist hart

Wenn man 50 mio braucht wieso verkauft er dann? Das macht kein Sinn?

Meine Fresse in was für ein Scheiß habe ich investiert :-( die sind ja so gut wie pleite

Also es kann Split geben und auch publik offerings, Achtung KANN

Furthermore, on March 20, 2024 (the “Effective Date”), we entered into a fourth amendment (the “Fourth Amendment”) to our Credit Agreement and Guaranty with Oaktree Fund Administration LLC (“Oaktree”) and the other lenders (together with Oaktree, the “Lenders”) and parties thereto, dated April 19, 2022 (as amended to date, the “Credit Agreement”) pursuant to which, we must raise by November 30, 2024 an aggregate of at least $50.0 million in gross proceeds from the issuance of our common stock, warrants and/or pre-funded warrants and other partnering transactions, the failure of which would constitute an event of default under the Credit Agreement. Since March 20, 2024, and as of April 10, 2024, we completed a financing transaction and issued 6.5 million shares of common stock and warrants to acquire 10.8 million shares of our common stock. As a result, as of April 10, 2024, we had 41,081,156 authorized shares of common stock remaining available for issuance. An increased number of authorized but unissued shares of common stock would allow us to take prompt action in regards to any issuances of our common stock, warrants and/or pre-funded warrants that would allow us to satisfy our obligations under the covenants in the Credit Agreement.

Bis 30.11.24 brauchen die einen bruttooerlös von 50 mio, um die Kreditvereinbarung zu erfüllen.

Our Board believes it is in the best interests of the Company and our stockholders to increase our authorized shares of common stock in order to have additional shares available for use as our Board deems appropriate or necessary, including to support current and anticipated future expenses and to ensure compliance with the minimum financing conditions under our Credit Agreement (as defined below). As such, the primary purpose of the Share Increase Amendment is to provide the Company with greater flexibility with respect to managing its common stock in connection with such corporate purposes as may, from time to time, be considered advisable by our Board. These corporate purposes could include, without limitation, financing activities, public or private offerings, stock dividends or splits, conversions of convertible securities, issuance of options and other equity awards pursuant to our stockholder-approved incentive plans, establishing a strategic relationship with a corporate partner and acquisition transactions. Having an increased number of authorized but unissued shares of common stock would allow us to take prompt action with respect to corporate opportunities that develop, without the delay and expense of convening a special meeting of stockholders for the purpose of approving an increase in our capitalization. Our Board would determine whether, when and on what terms the issuance of shares of common stock may be warranted in connection with any of the foregoing purposes.